Additional anti-HER2 antibodies, including the antibody drug conjugates trastuzumab-emtansine, and pertuzumab, which targets another region of the extra-cellular domain of HER2, improved survival in advanced and/or trastuzumab-resistant HER2-positive breast cancer [12, 13]. This evidence concerns the gene ERBB2 and breast carcinoma.